Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
company, contraction in the company conduct during the most recent fiscal period
delivered third quarter of 2022 operating shortfall of $-29.338 millions
Published Nov 06 2022
CSIMarket Team / CSIMarket.com
The brilliant policy to contextualize the most recent fiscal period result, at the current situation of the firm. Now, it's simple to compare the operating shortfall of the third quarter of 2021, as it came in $-22.791 millions.
The CEO is pursuing numerous corporate policies, in attempt to secure new service. Over the same period the net loss, which the company has dealt with amid the expanding span, has expanded to $-27.203 millions, from $-21.979 millions, relative to the Q3 of 2021.
Nuvation Bio Inc is expected to report next financial recent numbers on May 08, 2023.
Other NUVB's news
Nuvation Bio*s Strong Financials and Groundbreaking Research in Oncology Promise a Promising Future
The company declared operating deficit in the second quarter of 2023
Breaking News: Nuvation Bio Inc Takes on the Challenges of Fiscal First Quarter 2023
company, contraction in the company conduct during the most recent fiscal period
Other NUVB's news
Nuvation Bio*s Strong Financials and Groundbreaking Research in Oncology Promise a Promising Future
The company declared operating deficit in the second quarter of 2023
Breaking News: Nuvation Bio Inc Takes on the Challenges of Fiscal First Quarter 2023
company, contraction in the company conduct during the most recent fiscal period